<unk>  received FDA approval in January 2016. Its indication is for treatment of chronic hepatitis C of the genotypes 1 and 4 for adults. Hepatitis C is a global disease that infects upwards of 150 million people worldwide, especially in older generations. Hepatitis C causes inflammation of the liver that eventually leads to diminished liver function or even failure. Zepatier is indicated for treatment with or without use of ribavirin, as well. Zepatier has shown enough efficacy to be considered a first line of treatment for first-time patients with GT 1a and 1b, with or without cirrhosis. It is recommended for non-naive patients of the same genotypes, in addition to patients of GT4. Dosing There is one FDA approved dosing regimen. It consists of 50 mg of<unk>  and 100 mg of<unk> . Genetic testing for genotype 1 is recommended to determine if the patient is NS5A resistant before the initial treatment. This resistance results in a likely decrease in SRV12. Dosage is taken once daily over the most common span of 12-weeks.<unk>  is oftentimes prescribed with ribavirin for patients with renal impairment. "Zepatier is available as a beige-colored, oval-shaped, film-coated tablet debossed with "770" on one side and plain on the other." Patient population Treatment Duration Genotype 1a: Treatment-naïve or PegIFN/RBV-experienced without baseline NS5A polymorphisms Zepatier 12 weeks Genotype 1a: Treatment-naïve or PegIFN/RBV-experienced with baseline NS5A polymorphisms Zepatier + ribavirin 16 weeks Genotype 1b: Treatment-naïve or PegIFN/RBV-experienced Zepatier 12 weeks Genotype 1a§ or 1b: PegIFN/RBV/PI-experienced Zepatier + ribavirin 12 weeks Genotype 4: Treatment-naïve Zepatier 12 weeks Genotype 4: PegIFN/RBV-experienced Zepatier + ribavirin 16 weeks
Elbasvir/grazoprevir
Atazanavir/cobicistat
Atazanavir/ritonavir
Darunavir/cobicistat
Ombitasvir/paritaprevir/ritonavir
Nirmatrelvir/ritonavir
Cabotegravir/rilpivirine
Abacavir/lamivudine